<DOC>
	<DOC>NCT00404495</DOC>
	<brief_summary>This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.</brief_summary>
	<brief_title>Combination of Irinotecan and Temozolomide in Children With Brain Tumors.</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease. Cohort 2: Newlydiagnosed highgrade glioma (World Health Organization [WHO] grade 3 or 4) Life expectancy â‰¥ 3 months Diagnosis of brainstem glioma Concurrent administration of any other antitumor therapy Preexisting uncontrolled diarrhea</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>